Personalis (NASDAQ:PSNL) Stock Price Down 8.4% – Here’s What Happened

Personalis, Inc. (NASDAQ:PSNL)’s stock price was down 8.4% on Tuesday . The stock traded as low as $6.10 and last traded at $6.03. Approximately 371,380 shares changed hands during trading, a decline of 74% from the average daily volume of 1,425,307 shares. The stock had previously closed at $6.58.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on PSNL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Thursday, January 22nd. Needham & Company LLC lifted their price objective on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, February 27th. Guggenheim boosted their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, January 26th. BTIG Research boosted their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Finally, Morgan Stanley decreased their price target on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Personalis Trading Down 7.6%

The stock’s 50 day moving average is $8.03 and its 200 day moving average is $8.42. The firm has a market cap of $636.26 million, a price-to-earnings ratio of -6.70 and a beta of 2.20.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. The firm had revenue of $17.35 million for the quarter, compared to analyst estimates of $17.12 million. On average, equities research analysts predict that Personalis, Inc. will post -1.4 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PSNL. Caitong International Asset Management Co. Ltd grew its position in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of Personalis during the 2nd quarter worth approximately $30,000. International Assets Investment Management LLC acquired a new position in shares of Personalis during the 4th quarter worth approximately $31,000. BNP Paribas Financial Markets grew its position in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares in the last quarter. Finally, Focus Partners Wealth acquired a new position in shares of Personalis during the 1st quarter worth approximately $47,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.